David Danielsen

David Danielsen is a Boston-based operator-angel affiliated with CairnSurgical, writing $25K to $100K at pre-seed and seed into medical devices and diagnostics. The Cairn affiliation is the strongest signal: a surgical breast localization device company places him squarely in the surgical device commercialization world, which translates to operator value on regulatory strategy, clinical study design, surgeon adoption, and hospital purchasing dynamics. AI is not a focus, so model-first software pitches will not land unless the underlying product has a device or procedural anchor. Check size positions him as a single-conviction angel, useful as a clinical-operations advisor on the cap table rather than a round leader, with highest value to teams pre-FDA submission or early in surgeon adoption. Founders most likely to convert are early surgical and procedural device companies, diagnostic instrument startups selling into hospitals, and tech-enabled service models where a device backbone matters. Digital health, biotech, and consumer wellness are weaker fits. The Boston and broader Northeast surgical and device community will be the easiest geographic match for warm intros and pilot site work. The entry path is a LinkedIn message, ideally via a mutual Boston device or surgical investor connection, leading with the regulatory pathway, the surgeon user persona, and the specific question you want a device-commercialization veteran to answer. Founders without a clear FDA path or with no clinical champions identified will not survive due diligence with this profile of investor.